Citation Impact
Citing Papers
Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World
2006 Standout
Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials
2013 Standout
Screening for prostate cancer: A Cochrane systematic review
2007
Cancer burden in the year 2000. The global picture
2001 Standout
Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline
2010 Standout
Update on screening for prostate cancer with prostate-specific antigen
2004
Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter
2004 Standout
Use of doping agents, particularly anabolic steroids, in sports and society
2008 Standout
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
2017 Standout
Is dehydroepiandrosterone a hormone?
2005
Permutation tests for joinpoint regression with applications to cancer rates
2000 Standout
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
1996 Standout
Screening decreases prostate cancer mortality: 11‐year follow‐up of the 1988 Quebec prospective randomized controlled trial
2004
Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection
2018 StandoutNobel
Analysis of variation in prostate-specific antigen values
1993
Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate Cancer
2003
Optimization of phenolics and dietary fibre extraction from date seeds
2008 Standout
Epigenetics in Cancer
2008 Standout
DNA‐Based Detection of Prostate Cancer in Blood, Urine, and Ejaculates
2001
The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma
2005 Standout
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
EAU Guidelines on Prostate Cancer
2007 Standout
Comparable amounts of sex steroids are made outside the gonads in men and women: Strong lesson for hormone therapy of prostate and breast cancer
2008
Gene Silencing in Cancer in Association with Promoter Hypermethylation
2003 Standout
Prevention of Venous Thromboembolism
2004 Standout
A Risk-Benefit Assessment of Pharmacological Therapies for Hirsutism
2001
ACR Appropriateness Criteria Prostate Cancer—Pretreatment Detection, Staging, and Surveillance
2013
Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
2006
The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence declinein the United States
1998
PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2
2015 Standout
Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer
2011
Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European randomised screening for prostate cancer (ERSPC) trial
2001
Comparative Efficiency of Prostate-Specific Antigen Screening Strategies for Prostate Cancer Detection
2000
Polycystic ovary syndrome
2016 Standout
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
2006 Standout
A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma
2008
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
2014 Standout
Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized Controlled Trial
2006
Global cancer statistics in the year 2000
2001 Standout
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013
2013 Standout
Robotic radical prostatectomy: A technique to reduce pT2 positive margins
2004 StandoutNobel
INCIDENCE, ETIOLOGY, LOCATION, PREVENTION AND TREATMENT OF POSITIVE SURGICAL MARGINS AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCER
1998
Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens
2005
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
2012 Standout
Response to Flutamide Withdrawal in Advanced Prostate Cancer in Progression Under Combination Therapy
1993
CHARACTERISTICS OF SCREENING DETECTED PROSTATE CANCER IN MEN 50 TO 66 YEARS OLD WITH 3 TO 4 NG./ML. PROSTATE SPECIFIC ANTIGEN
1998
A Prospective Evaluation of Plasma Prostate-Specific Antigen for Detection of Prostatic Cancer
1995
Screening for prostate cancer
2013
EFFECT OF SOLUBLE AND INSOLUBLE FIBER DIETS ON SERUM PROSTATE SPECIFIC ANTIGEN IN MEN
2000
Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force
2008
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
1998 StandoutScience
Randomized, Prospective, Controlled Study Comparing Radical Prostatectomy Alone and Neoadjuvant Androgen Withdrawal in the Treatment of Localized Prostate Cancer
1996
Quantitative Methylation-Specific Polymerase Chain Reaction Gene Patterns in Urine Sediment Distinguish Prostate Cancer Patients From Control Subjects
2005
The diagnosis, management, treatment and costs of prostate cancer in England and Wales.
1997
Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force
2002
Cancer treatment and survivorship statistics, 2016
2016 Standout
Cancer statistics, 2015
2015 Standout
Cancer treatment and survivorship statistics, 2019
2019 Standout
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
2002 Standout
The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation
2013
15-Year Followup of a Population Based Prostate Cancer Screening Study
2009
Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force
2011
Diffusion-Weighted MRI in the Body: Applications and Challenges in Oncology
2007 Standout
Pathologic and Clinical Findings to Predict Tumor Extent of Nonpalpable (Stage T1 c) Prostate Cancer
1994 Standout
Prospective Evaluation Plan for Randomised Trials of Prostate Cancer Screening
1996
Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group.
1996
Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer
2006
Cancer de la prostate
2007
Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate Cancer
1995
Cancer treatment and survivorship statistics, 2014
2014 Standout
Works of Raul Suburu being referenced
Screening decreases prostate cancer death: First analysis of the 1988 Quebec Prospective Randomized Controlled Trial
1999
Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen
1996
Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer
2000
Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients
1992
Neoadjuvant hormonal therapy: The Canadian experience
1997
Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy.
1995
Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigen.
1993
Down-staging of early stage prostate cancer before radical prostatectomy: The first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist
1994
Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial.
1993
Serum Prostate Specific Antigen as Pre-Screening Test for Prostate Cancer
1992